This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Study of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
-
Mayo Clinic Jacksonville, Jacksonville, Florida, United States, 32224
University of Michigan, Ann Arbor, Michigan, United States, 48109
Mayo Clinic Rochester, Rochester, Minnesota, United States, 55905
Washington University St.Louis, Saint Louis, Missouri, United States, 63110
Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10021
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States, 27157
Gabrail Cancer Center Research, Canton, Ohio, United States, 44718
Cleveland Clinic, Cleveland, Ohio, United States, 44195
Oregon Health and Science University, Portland, Oregon, United States, 97239
Sargon Research - Pennsylvania Cancer Specialists and Research Center, Gettysburg, Pennsylvania, United States, 17325
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Disc Medicine, Inc,
Will Savage, MD PhD, STUDY_DIRECTOR, Disc Medicine
2024-10